Alphs Larry, Fu Dong-Jing, Williamson David, Jamieson Carol, Greist John, Harrington Magdalena, Lindenmayer Jean-Pierre, McCullumsmith Cheryl, Sheehan David V, Shelton Richard C, Wicks Paul, Canuso Carla M
Dr. Alphs is with Denovo Biopharma in San Diego, California (he was with Janssen Scientific Affairs, LLC in Titusville, New Jersey at the time the work reported herein was performed).
Drs. Fu and Canuso are with Janssen Research and Development, LLC in Titusville, New Jersey.
Innov Clin Neurosci. 2022 Apr-Jun;19(4-6):36-47.
Most assessments of suicidal ideation and behavior (SIB) are limited by reliance on a single assessor, typically a clinician or patient, with scant detail on patient-related drivers of SIB and inability to detect rapid change in SIB. Furthermore, many techniques do not include a semistructured interview, increasing rater variability. The Suicide Ideation and Behavior Assessment Tool (SIBAT) addresses these limitations.
More than 30 experts in scale development, statistics, and clinical management of suicidal patients collaborated over a greater than four-year period to develop the SIBAT. Input for content and validity was received from patients, clinicians, and regulatory authorities in the United States (US) and Europe. Psychometric properties of the SIBAT were evaluated in validation studies.
The SIBAT is organized into eight independent patient- or clinician-rated modules with branching logic and scoring algorithms, which necessitates computerization. Patient-reported information is first captured in Modules 1 to 5. Thereafter, an experienced clinician reviews the patient's report, conducts a semistructured interview (Module 6), and assesses the patient's suicide risk (Module 7) and optimal antisuicide management (Module 8). Input from cognitive interviews of diverse adult, adolescent, and clinician participants was incorporated into the final version of the SIBAT. Psychometric testing demonstrated good inter-rater reliability (intraclass coefficient range: 0.68-0.82), intra-rater reliability (weighted-kappa range: 0.64-0.76), and concurrent validity with other instruments for assessing SIB.
Patient- and clinician-based assessments and the psychometric studies summarized in this report support the validity and reliability of the SIBAT for capturing critical information related to assessment of SIB in adolescents and adults at risk for suicide.
大多数自杀意念和行为（SIB）评估存在局限性，依赖单一评估者，通常是临床医生或患者，对与患者相关的SIB驱动因素细节描述不足，且无法检测SIB的快速变化。此外，许多技术不包括半结构化访谈，增加了评分者的变异性。自杀意念和行为评估工具（SIBAT）解决了这些局限性。
30多位量表开发、统计学和自杀患者临床管理方面的专家在四年多的时间里合作开发了SIBAT。美国和欧洲的患者、临床医生和监管机构提供了有关内容和效度的意见。在验证研究中评估了SIBAT的心理测量特性。
SIBAT分为八个独立的患者或临床医生评分模块，具有分支逻辑和评分算法，这需要计算机化。患者报告的信息首先在模块1至5中收集。此后，经验丰富的临床医生会审查患者的报告，进行半结构化访谈（模块6），并评估患者的自杀风险（模块7）和最佳抗自杀管理（模块8）。来自不同成年、青少年和临床医生参与者的认知访谈的意见被纳入SIBAT的最终版本。心理测量测试显示出良好的评分者间信度（组内相关系数范围：0.68 - 0.82）、评分者内信度（加权kappa范围：0.64 - 0.76）以及与其他评估SIB工具的同时效度。
基于患者和临床医生的评估以及本报告中总结的心理测量研究支持SIBAT在捕捉与评估有自杀风险的青少年和成年人的SIB相关关键信息方面的效度和信度。
